SMPD1-mediated sphingolipid metabolism dysregulation in predicting and preventing in-stent restenosis of coronary heart disease patients

Journal of Pharmaceutical Analysis 2026 Open access

Read full text
Authors: Weiyu Meng, Y. Moydheen Sha, Ci-ren Zhong-ga, Hongxin Pan, Xiaobing Zhai, Pu Zhen, Henry H.Y. Tong, Edmundo Patricio Lopes Lao, Heng Zhang, Wenzhi Yang, Song Cui, Song Xiantao
+1 more Kefeng Li
DOI: 10.1016/j.jpha.2026.101553
Cited by: 0
References: 5

Abstract

• Network-based metabolomic biomarkers accurately predicts ISR in CTO patients. • Sphingolipid metabolism dysregulation is a key feature of ISR pathogenesis. • Identify SMPD1 as central regulator in ISR development. • Quinapril hydrochloride inhibits SMPD1 and reduces neointimal formation. • Combined biomarker-based prediction and SMPD1 targeting offers new ISR preventation management.

Fields of Study & Subjects

Sphingolipid Metabolism and Signaling Coronary Interventions and Diagnostics Metabolomics and Mass Spectrometry Studies

Publication details

Journal / source
Journal of Pharmaceutical Analysis
Volume
16
Issue
5
Pages
101553–101553
Publication date
16 January 2026
Language
EN